Form 4: Adverum Biotechnologies Director Granted Stock Options as Incentive

Adverum Biotechnologies, Inc. Director Mark L. Lupher, Jr. was granted 10,450 stock options with an exercise price of $2.32, vesting by June 2026.

Summary

• Mark L. Lupher, Jr., a Director of Adverum Biotechnologies, Inc. (ADVM), was granted 10,450 stock options.
• The options have an exercise price of $2.32 per share.
• The grant date for these options was June 17, 2025.
• The options will vest and become exercisable on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.
• Vesting is contingent on Mr. Lupher's continued service with the Issuer.
• Accelerated vesting will occur upon a change of control.
• The options expire on June 16, 2035.
• Following this transaction, Mr. Lupher beneficially owns 10,450 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive step in aligning management incentives with shareholder value, though it is a routine compensation event rather than a significant operational announcement.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, incentivizing long-term company performance.
• The options have a long expiration date (June 16, 2035), providing a significant window for potential value realization.

Negatives

• The options do not represent immediate equity ownership and are subject to a vesting schedule, meaning they are not immediately exercisable.
• The value of the options is dependent on the future stock price exceeding the exercise price of $2.32.

Risks

• The value of the stock options is subject to market fluctuations of Adverum Biotechnologies, Inc. common stock.
• Vesting is contingent on the director's continued service, meaning unvested options could be forfeited if service ceases before the vesting date.
• There is a risk that the stock price may not exceed the exercise price of $2.32, rendering the options worthless.

Future Outlook

The future outlook for the granted stock options is tied to the company's stock performance, with vesting expected by June 2026, subject to continued service.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology industry and publicly traded companies generally, serving as a form of long-term incentive compensation to align management and director interests with shareholder value creation.

Comparison to Industry Standards

• The specific grant of 10,450 stock options to a director is a standard equity compensation mechanism.
• Without detailed compensation benchmarks for similar-sized biotechnology companies or specific director roles, a direct quantitative comparison to industry standards for the amount of the grant is not feasible from this document alone.
• However, the use of stock options with vesting conditions and a long exercise period is consistent with common corporate governance practices aimed at incentivizing long-term performance.

Related Party Transactions

• The grant of stock options to Mark L. Lupher, Jr., a Director of Adverum Biotechnologies, Inc., constitutes a related party transaction as it involves compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance. It also represents a potential future dilution if options are exercised.
• Employees: No direct impact mentioned for general employees.

Next Steps

• The stock options are expected to vest on the earlier of June 17, 2026, or the 2026 annual meeting of stockholders.
• The reporting person may exercise the options at any time after vesting and before the expiration date of June 16, 2035, subject to the stock price being above the exercise price.

Key Dates

Keywords

ADVM, Adverum Biotechnologies, stock options, Form 4, insider transaction, director compensation, equity grant